论文部分内容阅读
920例患者接受Moricizine治疗,用药期间,49例发生了CHF。使用Moricizine之前,374例伴有CHF病史,可耐受Moricizine治疗的326例患者,用药期间未见发生CHF(平均治疗97±217天)。374例患者于Moricizine治疗中,48例(12.8%)出现CHF复发或恶化,其中21例停药,28例继续用药,但未见发生CHF。546例无CHF病史的患者,在治疗期间,仅1例(0.2%)发生CHF。发生CHF患者的平均左心室射血分数(LVEF)为26%。大多数患者接受Moricizine的剂量为每天600～1050mg,最大剂量每天
920 patients received Moricizine treatment, 49 patients during the treatment of CHF. Prior to Moricizine, 374 patients with a history of CHF who were tolerated by Moricizine had no CHF during the medication period (median, 97 ± 217 days). Of the 374 patients who received Moricizine, 48 (12.8%) had a relapse or worsening of CHF, of which 21 discontinued and 28 remained on, but no CHF occurred. In 546 patients without a history of CHF, only 1 patient (0.2%) developed CHF during the treatment period. The mean left ventricular ejection fraction (LVEF) of CHF patients was 26%. Most patients receive Moricizine 600 to 1050 mg daily, with the maximum daily dose